SCHEMBL582472

SCHEMBL582472

CCn1ncc2c(Nc3ccncc3)c(C3=NOC4(CCC4)C3)cnc21

nearest known ligand 0.39

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 14/20 0.39
PDE7A Q13946 2/20 0.38
ABL1 P00519 1/20 0.33
BCR P11274 1/20 0.33
BCDIN3D Q7Z5W3 1/20 0.33
PDE5A O76074 1/20 0.32
PDE3B Q13370 1/20 0.32
PDE3A Q14432 1/20 0.32
CDK4 P11802 1/20 0.31
CCND1 P24385 1/20 0.31
CCND2 P30279 1/20 0.31
CCND3 P30281 1/20 0.31
XDH P47989 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL582969 0.98 PDE4B (0.39) PDE4BPDE7AABL1BCRBCDIN3D
SCHEMBL582476 0.97 PDE4B (0.39) PDE4BPDE7AABL1BCRBCDIN3D
SCHEMBL582190 0.91 PDE4B (0.48) PDE4BPDE7AABL1BCRPDE3B
SCHEMBL583063 0.90 PDE4B (0.40) PDE4BPDE7ABCDIN3DPDE3BPDE3A
SCHEMBL582204 0.90 PDE4B (0.39) PDE4BPDE7AABL1BCRPDE5A
SCHEMBL583252 0.90 PDE4B (0.48) PDE4BPDE7AABL1BCRBCDIN3D
SCHEMBL582884 0.89 PDE4B (0.48) PDE4BPDE7AABL1BCRBCDIN3D
SCHEMBL582707 0.88 PDE4B (0.40) PDE4BPDE7ABCDIN3DPDE3BPDE3A
SCHEMBL582987 0.88 PDE4B (0.39) PDE4BPDE7AABL1BCRPDE5A
SCHEMBL583350 0.88 PDE4B (0.39) PDE4BPDE7APDE5APDE3BPDE3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8420666-B2 Pyrazolo (3, 4-B) pyridine derivatives as phosphodiesterase inhibitors RANBAXY LABORATORIES LIMITED (IN) 2013-04-16 US claimed
EP-2124944-B1 Pyrazolo[3,4-b]pyridine derivatives as phosphodiesterase inhibitors RANBAXY LAB LTD (IN) 2012-02-15 EP claimed
US-20100292196-A1 PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2010-11-18 US claimed
US-8420666-B2 Pyrazolo (3, 4-B) pyridine derivatives as phosphodiesterase inhibitors RANBAXY LABORATORIES LIMITED (IN) 2013-04-16 US disclosed
EP-2124944-B1 Pyrazolo[3,4-b]pyridine derivatives as phosphodiesterase inhibitors RANBAXY LAB LTD (IN) 2012-02-15 EP disclosed
US-20100292196-A1 PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2010-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292196-A1 PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS PDE3B, PDE4A, PDE3A PDE4B 5/4885PDE7A 4/4885ABL1 1108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.